{"nctId":"NCT02263326","briefTitle":"Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure","startDateStruct":{"date":"2014-12"},"conditions":["HIV Infection"],"count":89,"armGroups":[{"label":"dolutegravir plus lamivudine","type":"EXPERIMENTAL","interventionNames":["Drug: dolutegravir","Drug: lamivudine"]},{"label":"Continue current ART regimen","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Continue current antiretroviral regimen"]}],"interventions":[{"name":"dolutegravir","otherNames":["TIVICAY, DTG"]},{"name":"lamivudine","otherNames":["EPIVIR, 3TC"]},{"name":"Continue current antiretroviral regimen","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* HIV-1 Infection\n* HIV-1 RNA \\<50 copies/mL on all measurements within 48 weeks prior to study entry while on any DHHS recommended or alternative three-drug antiretroviral regimen. (A history of switching for simplification and/or tolerability is allowed. At least two measurements within the previous 48 weeks are required prior to study screening.)\n* No history of virologic failure, defined as consecutive HIV RNA \\> 50 copies/mL after 12 months of initiating ART. An isolated (non-consecutive) HIV RNA \\> 50 copies/mL (but less than 400 copies/mL) is permitted after 12 months of initiating ART but not in the 48-week window prior to study entry.\n* Screening plasma HIV RNA \\< 20 copies/mL using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test V2.0, obtained within 45 days prior to study entry\n* Nadir CD4 count \\>200 cells/mm\n* Pretreatment genotype documenting no mutations in the protease or reverse transcriptase genes\n* No known resistance to integrase inhibitors\n* Laboratory values obtained within 45 days prior to study entry:\n\nANC \\>750 Hemoglobin \\>10 g/dL Platelets \\>50,000 Calculated creatinine clearance (CrCl) \\>50 mL/min\n\n* Negative serum or urine pregnancy test\n* Men and women age greater or equal to 18 years.\n* Ability to continue current regimen (i.e, have uninterrupted access)\n* No evidence of chronic hepatitis B\n\nExclusion Criteria:\n\n* Serious illness or AIDS-related complication within 21 days of screening requiring systemic treatment and/or hospitalization\n* Treatment within 30 days prior to study entry with immune modulators\n* Vaccination within 7 days\n* Active HCV treatment or anticipated need for treatment within study period. (HCV infection alone is not exclusionary)\n* Unstable liver disease or severe hepatic impairment\n* Known allergy or hypersensitivity to DTG or lamivudine.\n* Active drug or alcohol use or dependence that could interfere with adherence to study requirements\n* ALT (alanine aminotransferase) \\>5 x ULN (upper limit of normal) OR ALT \\>3 x ULN and total bilirubin \\>1.5 x ULN (with 35% direct bilirubin)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Participants With Treatment Failure","description":"Proportion of participants with treatment failure (defined as virologic failure (HIV RNA \\>50 copies/mL), loss to follow-up, or treatment discontinuation) between those who switch to DTG + lamivudine and those who continue their current ART regimen","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0682","spread":null},{"groupId":"OG001","value":"0.0667","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants With Virologic Success","description":"Proportion of participants with virologic success (\\<50 copies/mL) based on FDA snapshot definition","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9091","spread":null},{"groupId":"OG001","value":"0.8889","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in CD4 Count From Baseline to Week 48","description":"Change in CD4 count between arms will be presented in the attached statistical analysis table","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Total Cholesterol From Baseline to Week 48","description":"Change in Total Cholesterol between arms will be presented in the attached statistical analysis table","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"-1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in LDL Cholesterol From Baseline to Week 48","description":"Change in Low-density lipoprotein (LDL) cholesterol between arms will be presented in the attached statistical analysis table","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"-3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Creatinine Clearance From Baseline to Week 48","description":"Change in Creatinine Clearance between arms will be presented in the attached statistical analysis table","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Drug Resistance Associated Mutations","description":"Drug resistance mutations measured by HIV genotyping in patients with confirmed virologic failure","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Residual Viremia by HIV-1 Single-copy Assay","description":"Difference in HIV-1 detection by the HIV-1 single copy assay between arms will be presented in statistical analysis","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"7.0"},{"groupId":"OG001","value":"4.2","spread":"6.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":44},"commonTop":["Grade 3 bilirubinemia"]}}}